{"transactions":[{"id":687653,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-13T21:00:04.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":30350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":30350,"derivative":{"exercise_price":31,"expiration_date":"2036-08-12","underlying":"Ordinary Shares","underlying_shares":30350},"source":{"system":"sec-edgar","filing":"0001193125-26-349537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778307/000119312526349537/ownership.xml","form_type":"4"}},{"id":763182,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:22:59.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001778307-26-000002","document":"form4-05262026_080555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778307/000177830726000002/form4-05262026_080555.xml","form_type":"4"}},{"id":976221,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976220,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":234000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":21.09,"expiration_date":"2029-12-13","underlying":"Common Stock","underlying_shares":234000},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976219,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":238973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.35,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":238973},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976218,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":87220,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":87220},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976217,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":165289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":165289},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976216,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23809,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976215,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":233252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":42.95,"expiration_date":"2032-12-09","underlying":"Common Stock","underlying_shares":233252},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976214,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":374985,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":19.87,"expiration_date":"2033-12-08","underlying":"Common Stock","underlying_shares":374985},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976213,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":292179,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":29.23,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":292179},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976212,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.35,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":3527},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976211,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4739,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":4739},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976210,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2328,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":42.95,"expiration_date":"2032-12-09","underlying":"Common Stock","underlying_shares":2328},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976209,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5032,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":19.87,"expiration_date":"2033-12-08","underlying":"Common Stock","underlying_shares":5032},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976208,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3421,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":29.23,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":3421},"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976207,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":159762,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":976206,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-09T10:24:17.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":277075,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312131","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312131/ownership.xml","form_type":"4"}},{"id":991414,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-21T18:25:28.000Z","date":"2025-11-20","kind":"gift","planned":false,"acquired":false,"shares":74538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock that the reporting person donated as a gift to a donor advised fund."}],"balance_after":436837,"source":{"system":"sec-edgar","filing":"0001193125-25-291688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525291688/ownership.xml","form_type":"4"}},{"id":1000294,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-13T20:03:31.000Z","date":"2025-11-12","kind":"gift","planned":false,"acquired":false,"shares":14739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a bona fide charitable gift to a 501(c)(3) organization.  The Reporting Person does not have any pecuniary interest in the 501(c)(3) organization."}],"balance_after":511375,"source":{"system":"sec-edgar","filing":"0001193125-25-280748","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525280748/ownership.xml","form_type":"4"}},{"id":1019307,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-14T20:11:47.000Z","date":"2025-10-10","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023."}],"balance_after":380017,"derivative":{"exercise_price":19.87,"expiration_date":"2033-12-07","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-239343","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525239343/ownership.xml","form_type":"4"}},{"id":1019306,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-14T20:11:47.000Z","date":"2025-10-10","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":53.978,"value":1619340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.92 to $54.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":526114,"source":{"system":"sec-edgar","filing":"0001193125-25-239343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525239343/ownership.xml","form_type":"4"}},{"id":1019305,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-14T20:11:47.000Z","date":"2025-10-10","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":19.87,"value":596100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."}],"balance_after":556114,"source":{"system":"sec-edgar","filing":"0001193125-25-239343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525239343/ownership.xml","form_type":"4"}},{"id":1020839,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T18:58:03.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":52212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.615,"expiration_date":"2028-09-07","underlying":"Common Stock","underlying_shares":52212},"source":{"system":"sec-edgar","filing":"0001193125-25-236151","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525236151/ownership.xml","form_type":"4"}},{"id":1020838,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-09T18:58:03.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":52212,"price":0.615,"value":32110.38,"ownership":{"direct":true},"balance_after":526114,"source":{"system":"sec-edgar","filing":"0001193125-25-236151","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525236151/ownership.xml","form_type":"4"}},{"id":1041636,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":false,"shares":1919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023."}],"balance_after":410017,"derivative":{"exercise_price":19.87,"expiration_date":"2033-12-07","underlying":"Common Stock","underlying_shares":1919},"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041635,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":false,"shares":13022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.364,"expiration_date":"2029-01-15","underlying":"Common Stock","underlying_shares":13022},"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041634,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-11","kind":"sale","planned":true,"acquired":false,"shares":1796,"price":43.02,"value":77263.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":473902,"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041633,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":158,"price":44.62,"value":7049.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."}],"balance_after":475698,"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041632,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":7317,"price":43.995,"value":321911.415,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.58 to $44.33, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":475856,"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041631,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":22525,"price":42.994,"value":968439.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.58 to $43.57, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":483173,"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041630,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":true,"shares":1919,"price":19.87,"value":38130.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."}],"balance_after":505698,"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1041629,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-12T20:36:05.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":true,"shares":13022,"price":6.364,"value":82872.008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."}],"balance_after":503779,"source":{"system":"sec-edgar","filing":"0000950170-25-114661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/ownership.xml","form_type":"4"}},{"id":1067831,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-13T18:37:07.000Z","date":"2025-08-11","kind":"sale","planned":true,"acquired":false,"shares":400,"price":49.435,"value":19774.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.43 to $49.44, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":490757,"source":{"system":"sec-edgar","filing":"0000950170-25-108232","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025108232/ownership.xml","form_type":"4"}},{"id":1067830,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-13T18:37:07.000Z","date":"2025-08-11","kind":"sale","planned":true,"acquired":false,"shares":18805,"price":48.865,"value":918906.325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.41 to $49.39, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":491157,"source":{"system":"sec-edgar","filing":"0000950170-25-108232","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025108232/ownership.xml","form_type":"4"}},{"id":1067829,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-13T18:37:07.000Z","date":"2025-08-11","kind":"sale","planned":true,"acquired":false,"shares":10795,"price":48.07,"value":518915.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.40 to $48.39, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":509962,"source":{"system":"sec-edgar","filing":"0000950170-25-108232","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025108232/ownership.xml","form_type":"4"}},{"id":1088623,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-11T18:30:05.000Z","date":"2025-07-10","kind":"sale","planned":true,"acquired":false,"shares":15314,"price":51.732,"value":792223.848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.06 to $52.05, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":520757,"source":{"system":"sec-edgar","filing":"0000950170-25-095409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025095409/ownership.xml","form_type":"4"}},{"id":1088622,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-11T18:30:05.000Z","date":"2025-07-10","kind":"sale","planned":true,"acquired":false,"shares":14686,"price":50.57,"value":742671.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.03 to $50.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":536071,"source":{"system":"sec-edgar","filing":"0000950170-25-095409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025095409/ownership.xml","form_type":"4"}},{"id":1095273,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-02T18:00:09.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":890,"price":23.868,"value":21242.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Cheng is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025."}],"balance_after":550757,"source":{"system":"sec-edgar","filing":"0000950170-25-093316","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025093316/ownership.xml","form_type":"4"}},{"id":1105060,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-20T21:09:06.000Z","date":"2025-06-18","kind":"sale","planned":false,"acquired":false,"shares":6620,"price":54.84,"value":363040.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.73 to $54.84, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":549867,"source":{"system":"sec-edgar","filing":"0000950170-25-088641","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025088641/ownership.xml","form_type":"4"}},{"id":1113521,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-12T18:34:13.000Z","date":"2025-06-10","kind":"sale","planned":true,"acquired":false,"shares":7837,"price":53.994,"value":423150.978,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.128 to $54.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":556487,"source":{"system":"sec-edgar","filing":"0000950170-25-085674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025085674/ownership.xml","form_type":"4"}},{"id":1113520,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-12T18:34:13.000Z","date":"2025-06-10","kind":"sale","planned":true,"acquired":false,"shares":15158,"price":54.353,"value":823882.774,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.08 to $54.353,\n inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":564324,"source":{"system":"sec-edgar","filing":"0000950170-25-085674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025085674/ownership.xml","form_type":"4"}},{"id":1113519,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-12T18:34:13.000Z","date":"2025-06-10","kind":"sale","planned":true,"acquired":false,"shares":14842,"price":53.76,"value":797905.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.075 to $54.07, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":579482,"source":{"system":"sec-edgar","filing":"0000950170-25-085674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025085674/ownership.xml","form_type":"4"}},{"id":1144662,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:05:20.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013408","document":"form4-05162025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778307/000141588925013408/form4-05162025_080509.xml","form_type":"4"}},{"id":1150935,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-13T21:11:49.000Z","date":"2025-05-12","kind":"sale","planned":true,"acquired":false,"shares":22800,"price":41.634,"value":949255.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.32 to $41.96, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":594324,"source":{"system":"sec-edgar","filing":"0000950170-25-070811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025070811/ownership.xml","form_type":"4"}},{"id":1150934,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-13T21:11:49.000Z","date":"2025-05-12","kind":"sale","planned":true,"acquired":false,"shares":7200,"price":41,"value":295200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.32 to $41.31, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":617124,"source":{"system":"sec-edgar","filing":"0000950170-25-070811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025070811/ownership.xml","form_type":"4"}},{"id":1173312,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-11T18:00:05.000Z","date":"2025-04-10","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":35.226,"value":1056780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.56, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":624324,"source":{"system":"sec-edgar","filing":"0000950170-25-053391","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025053391/ownership.xml","form_type":"4"}},{"id":1205773,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-14T21:18:12.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":1738,"price":44.88,"value":78001.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":654324,"source":{"system":"sec-edgar","filing":"0000950170-25-039765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025039765/ownership.xml","form_type":"4"}},{"id":1209723,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-12T18:00:04.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":1216,"price":42.313,"value":51452.608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.226 to $42.500, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":656062,"source":{"system":"sec-edgar","filing":"0000950170-25-038177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025038177/ownership.xml","form_type":"4"}},{"id":1209722,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-12T18:00:04.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":28784,"price":41.746,"value":1201616.864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.22 to $42.21, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":657278,"source":{"system":"sec-edgar","filing":"0000950170-25-038177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025038177/ownership.xml","form_type":"4"}},{"id":1274074,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:58.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":200,"price":55.81,"value":11162.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."}],"balance_after":686062,"source":{"system":"sec-edgar","filing":"0000950170-25-018311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025018311/ownership.xml","form_type":"4"}},{"id":1274073,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:58.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":749,"price":54.546,"value":40854.954,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.355 to $54.930, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":686262,"source":{"system":"sec-edgar","filing":"0000950170-25-018311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025018311/ownership.xml","form_type":"4"}},{"id":1274072,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:58.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":9972,"price":53.666,"value":535157.352,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.355 to $54.345, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":687011,"source":{"system":"sec-edgar","filing":"0000950170-25-018311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025018311/ownership.xml","form_type":"4"}},{"id":1274071,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:58.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":6439,"price":52.908,"value":340674.612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.350 to $53.345, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":696983,"source":{"system":"sec-edgar","filing":"0000950170-25-018311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025018311/ownership.xml","form_type":"4"}},{"id":1274070,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-11T21:30:58.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":12640,"price":51.752,"value":654145.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.340 to $52.330, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":703422,"source":{"system":"sec-edgar","filing":"0000950170-25-018311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025018311/ownership.xml","form_type":"4"}},{"id":1291852,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-29T20:43:04.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":3377,"price":56.89,"value":192117.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $56.430 to $57.010, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":716062,"source":{"system":"sec-edgar","filing":"0000950170-25-010705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025010705/ownership.xml","form_type":"4"}},{"id":1291851,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-29T20:43:04.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":2381,"price":55.53,"value":132216.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.255 to $56.010, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":719439,"source":{"system":"sec-edgar","filing":"0000950170-25-010705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025010705/ownership.xml","form_type":"4"}},{"id":1291850,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-29T20:43:04.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":24242,"price":54.56,"value":1322643.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.190 to $55.165, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":721820,"source":{"system":"sec-edgar","filing":"0000950170-25-010705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025010705/ownership.xml","form_type":"4"}},{"id":1294517,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T18:07:48.000Z","date":"2025-01-23","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are vested and currently exercisable."}],"balance_after":52212,"derivative":{"exercise_price":0.615,"expiration_date":"2028-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-009324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025009324/ownership.xml","form_type":"4"}},{"id":1294516,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-27T18:07:48.000Z","date":"2025-01-23","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0.615,"value":30750.0,"ownership":{"direct":true},"balance_after":746062,"source":{"system":"sec-edgar","filing":"0000950170-25-009324","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025009324/ownership.xml","form_type":"4"}},{"id":1326774,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-18T20:50:13.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":295600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":295600,"derivative":{"exercise_price":29.23,"expiration_date":"2034-12-15","underlying":"Common Stock","underlying_shares":295600},"source":{"system":"sec-edgar","filing":"0000950170-24-138132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024138132/ownership.xml","form_type":"4"}},{"id":1326773,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-18T20:50:13.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":98500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":696062,"source":{"system":"sec-edgar","filing":"0000950170-24-138132","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024138132/ownership.xml","form_type":"4"}},{"id":1333940,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-12T20:24:50.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":7855,"price":30.79,"value":241855.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $30.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":597562,"source":{"system":"sec-edgar","filing":"0000950170-24-136017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024136017/ownership.xml","form_type":"4"}},{"id":1343009,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T19:36:36.000Z","date":"2024-12-02","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are vested and currently exercisable."}],"balance_after":111029,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000950170-24-133435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024133435/ownership.xml","form_type":"4"}},{"id":1343008,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-04T19:36:36.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":32.09,"value":802250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.59 to $32.54, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-133435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024133435/ownership.xml","form_type":"4"}},{"id":1343007,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-04T19:36:36.000Z","date":"2024-12-02","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":21.1,"value":527500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."}],"balance_after":630417,"source":{"system":"sec-edgar","filing":"0000950170-24-133435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024133435/ownership.xml","form_type":"4"}},{"id":1375546,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-05T09:00:35.000Z","date":"2024-11-01","kind":"exercise","planned":true,"acquired":false,"shares":27086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options are vested and currently exercisable."}],"balance_after":136029,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000950170-24-121100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024121100/ownership.xml","form_type":"4"}},{"id":1375545,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-05T09:00:35.000Z","date":"2024-11-01","kind":"exercise","planned":true,"acquired":false,"shares":81280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options are vested and currently exercisable."}],"balance_after":163115,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000950170-24-121100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024121100/ownership.xml","form_type":"4"}},{"id":1375544,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-05T09:00:35.000Z","date":"2024-11-01","kind":"sale","planned":true,"acquired":false,"shares":27086,"price":32.499,"value":880267.914,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.10 to $32.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-121100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024121100/ownership.xml","form_type":"4"}},{"id":1375543,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-05T09:00:35.000Z","date":"2024-11-01","kind":"exercise","planned":true,"acquired":true,"shares":27086,"price":21.1,"value":571514.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."}],"balance_after":632503,"source":{"system":"sec-edgar","filing":"0000950170-24-121100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024121100/ownership.xml","form_type":"4"}},{"id":1375542,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-05T09:00:35.000Z","date":"2024-11-01","kind":"sale","planned":true,"acquired":false,"shares":81280,"price":31.472,"value":2558044.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $32.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-121100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024121100/ownership.xml","form_type":"4"}},{"id":1375541,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-05T09:00:35.000Z","date":"2024-11-01","kind":"exercise","planned":true,"acquired":true,"shares":81280,"price":21.1,"value":1715008.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."}],"balance_after":686697,"source":{"system":"sec-edgar","filing":"0000950170-24-121100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024121100/ownership.xml","form_type":"4"}},{"id":1384128,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Righto Buy)","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":false,"shares":63539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vested and currently exercisable."}],"balance_after":93709,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":185343},"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384127,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Righto Buy)","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":false,"shares":3103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vested and currently exercisable."}],"balance_after":157248,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":185343},"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384126,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Righto Buy)","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-16","kind":"exercise","planned":true,"acquired":false,"shares":24992,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are vested and currently exercisable."}],"balance_after":160351,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":185343},"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384125,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":226,"price":32.12,"value":7259.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.13, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384124,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":63313,"price":31.527,"value":1996068.951,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $32.07, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":605643,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384123,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":true,"shares":63539,"price":21.1,"value":1340672.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."}],"balance_after":668956,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384122,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":3103,"price":31.118,"value":96559.154,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.22, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384121,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":true,"shares":3103,"price":21.1,"value":65473.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."}],"balance_after":608520,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384120,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-16","kind":"sale","planned":true,"acquired":false,"shares":24992,"price":31.136,"value":778150.912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.22, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1384119,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:57:33.000Z","date":"2024-10-16","kind":"exercise","planned":true,"acquired":true,"shares":24992,"price":21.1,"value":527331.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person."}],"balance_after":630409,"source":{"system":"sec-edgar","filing":"0000950170-24-115731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024115731/ownership.xml","form_type":"4"}},{"id":1407706,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-13T17:10:03.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":1738,"price":26.18,"value":45500.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":605417,"source":{"system":"sec-edgar","filing":"0000950170-24-106451","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024106451/ownership.xml","form_type":"4"}},{"id":1427694,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T11:45:48.000Z","date":"2024-08-16","kind":"exercise","planned":false,"acquired":false,"shares":24538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.615,"expiration_date":"2028-10-17","underlying":"Common Stock","underlying_shares":24538},"source":{"system":"sec-edgar","filing":"0000950170-24-098933","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024098933/ownership.xml","form_type":"4"}},{"id":1427693,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-20T11:45:48.000Z","date":"2024-08-16","kind":"exercise","planned":false,"acquired":true,"shares":24538,"price":0.615,"value":15090.87,"ownership":{"direct":true},"balance_after":607155,"source":{"system":"sec-edgar","filing":"0000950170-24-098933","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024098933/ownership.xml","form_type":"4"}},{"id":1463154,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-02T18:55:46.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":1064,"price":19.941,"value":21217.224,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Cheng is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024."}],"balance_after":582617,"source":{"system":"sec-edgar","filing":"0000950170-24-080922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024080922/ownership.xml","form_type":"4"}},{"id":1480787,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-13T18:01:43.000Z","date":"2024-06-11","kind":"sale","planned":false,"acquired":false,"shares":7894,"price":22.641,"value":178728.054,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.640 to $22.760, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":581553,"source":{"system":"sec-edgar","filing":"0000950170-24-073181","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024073181/ownership.xml","form_type":"4"}},{"id":1510308,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-17T20:08:44.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":42.69,"expiration_date":"2034-05-14","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-24-013470","document":"form4-05172024_080535.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778307/000141588924013470/form4-05172024_080535.xml","form_type":"4"}},{"id":1574828,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-15T16:43:18.000Z","date":"2024-03-13","kind":"sale","planned":false,"acquired":false,"shares":1969,"price":28.33,"value":55781.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":589447,"source":{"system":"sec-edgar","filing":"0000950170-24-032263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024032263/ownership.xml","form_type":"4"}},{"id":1591795,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"exercise","planned":true,"acquired":false,"shares":17267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options are vested and currently exercisable."}],"balance_after":244395,"derivative":{"exercise_price":21.1,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":17267},"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591794,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"exercise","planned":true,"acquired":false,"shares":57733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options are vested and currently exercisable."}],"balance_after":10000,"derivative":{"exercise_price":16,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":57733},"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591793,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":114,"price":36.28,"value":4135.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"}],"balance_after":591416,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591792,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":7995,"price":35.4941,"value":283775.3295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.245 to $36.16, inclusive."}],"balance_after":591530,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591791,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":14680,"price":34.6303,"value":508372.804,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.19 to $35.18, inclusive."}],"balance_after":599525,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591790,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":9614,"price":33.8326,"value":325266.6164,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.18, inclusive."}],"balance_after":614205,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591789,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":6770,"price":32.2803,"value":218537.631,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.85, inclusive."}],"balance_after":623819,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591788,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":35827,"price":31.4002,"value":1124974.9654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.11 to $32.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4."}],"balance_after":630589,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591787,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"exercise","planned":true,"acquired":true,"shares":17267,"price":21.1,"value":364333.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"}],"balance_after":666416,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1591786,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-06T20:14:26.000Z","date":"2024-03-04","kind":"exercise","planned":true,"acquired":true,"shares":57733,"price":16,"value":923728.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023."}],"balance_after":649149,"source":{"system":"sec-edgar","filing":"0000950170-24-027510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024027510/ownership.xml","form_type":"4"}},{"id":1692745,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-03T17:00:09.000Z","date":"2024-01-02","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are vested and currently exercisable."}],"balance_after":24538,"derivative":{"exercise_price":0.615,"expiration_date":"2028-10-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-001053","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024001053/ownership.xml","form_type":"4"}}],"next_cursor":"2024-01-03T17:00:09.000000Z,1692745"}